Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Spectrum Pharma Inc (SPPI)

Spectrum Pharma Inc (SPPI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 914,134
  • Shares Outstanding, K 112,856
  • Annual Sales, $ 109,330 K
  • Annual Income, $ -120,010 K
  • 60-Month Beta 2.57
  • Price/Sales 9.18
  • Price/Cash Flow N/A
  • Price/Book 3.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.26
  • Number of Estimates 1
  • High Estimate -0.26
  • Low Estimate -0.26
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.40 +11.49%
on 10/14/19
8.95 -7.82%
on 11/11/19
+0.74 (+9.93%)
since 10/11/19
3-Month
6.90 +19.57%
on 09/03/19
9.98 -17.33%
on 09/17/19
+0.32 (+4.04%)
since 08/13/19
52-Week
6.22 +32.64%
on 12/20/18
14.65 -43.69%
on 12/03/18
-4.54 (-35.50%)
since 11/13/18

Most Recent Stories

More News
Best Relative Performance in the Biotechnology Industry Detected in Shares of Invitae Corp (NVTA , SGMO , SPPI , REGN , SGEN )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

NVTA : 17.38 (+0.81%)
SGMO : 9.69 (+0.73%)
SPPI : 8.25 (+1.85%)
Spectrum Pharmac Set to Possibly Pullback After Yesterday's Rally of 12.11%

Spectrum Pharmac (NASDAQ:SPPI) traded in a range yesterday that spanned from a low of $8.02 to a high of $8.93. Yesterday, the shares gained 12.1%, which took the trading range above the 3-day high of...

SPPI : 8.25 (+1.85%)
Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis

Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.

ALKS : 19.39 (-2.54%)
AVEO : 0.71 (+26.09%)
ANIK : 60.53 (+0.13%)
SPPI : 8.25 (+1.85%)
Spectrum Pharma: 3Q Earnings Snapshot

HENDERSON, Nev. (AP) _ Spectrum Pharmaceuticals Inc. (SPPI) on Thursday reported a loss of $26 million in its third quarter.

SPPI : 8.25 (+1.85%)
Spectrum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Pipeline Update

--Basket trial initiated to study poziotinib in patients with EGFR or HER2 mutation-positive malignant solid tumors in an investigator-led study at The University of Texas MD Anderson Cancer Center

SPPI : 8.25 (+1.85%)
Spectrum Pharmaceuticals Announces Third Quarter 2019 Financial Results Conference Call

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the third...

SPPI : 8.25 (+1.85%)
Spectrum Pharmaceuticals Announces Submission to the U.S. Food and Drug Administration of Updated Biologics License Application for ROLONTIS(R)

--ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs.

SPPI : 8.25 (+1.85%)
Is the Options Market Predicting a Spike in Spectrum Pharma (SPPI) Stock?

Investors need to pay close attention to Spectrum Pharma (SPPI) stock based on the movements in the options market lately.

SPPI : 8.25 (+1.85%)
Spectrum Pharmaceuticals Announces Publication of Positive Poziotinib Data in Cancer Cell

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today a publication from The University of Texas, MD Anderson Cancer...

SPPI : 8.25 (+1.85%)
FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia

FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.

AZN : 47.82 (+1.57%)
SPPI : 8.25 (+1.85%)
FGEN : 34.58 (-2.76%)
VRCA : 14.95 (+1.56%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Trade SPPI with:

Business Summary

Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and...

See More

Key Turning Points

2nd Resistance Point 8.74
1st Resistance Point 8.49
Last Price 8.25
1st Support Level 8.00
2nd Support Level 7.76

See More

52-Week High 14.65
Fibonacci 61.8% 11.43
Fibonacci 50% 10.43
Fibonacci 38.2% 9.44
Last Price 8.25
52-Week Low 6.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar